Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
Tenax Therapeutics, Inc. (NASDAQ: TENX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Tenax Therapeutics, Inc. (NASDAQ: TENX) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $16.00 price target on the stock.
Tenax Therapeutics, Inc. (NASDAQ: TENX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $16.00 price target on the stock.